Blood Cancer Precursor may Increase the Risk of Cancer Even after 30 Years

The risk of developing multiple myeloma (a form of blood cancer) increases in patients with monoclonal gammopathy of undetermined significance (MGUS) even after 30 years of stability. MGUS is a condition in which an abnormal protein, known as monoclonal protein or M protein, is found in the blood.

MGUS normally do not cause problems, but may sometimes progress into multiple myeloma. The study was led by Mayo Clinic research team and the findings are published in New England Journal of Medicine.

‘Patients with MGUS who develop multiple myeloma may have a shorter survival than people without the condition.’

"Monoclonal gammopathy of undetermined significance is present in more than 3 percent of the general population age 50 and older," says S. Vincent Rajkumar, M.D., a hematologist at Mayo Clinic and senior author of the study. "In some cases, people with monoclonal gammopathy of undetermined significance go on to develop multiple myeloma."

In their study, Dr. Rajkumar and his colleagues found that the overall risk of progression to myeloma or a related disorder is relatively small at 1 percent each year; however, the risk persists indefinitely. Scientists also noted that risk of myeloma or related cancer was relatively small, compared to other general causes of death. As a result, they recommend that patients who are followed for monoclonal gammopathy of undetermined significance not only be checked for presence or absence of progression, but also receive all other routine preventive services appropriate for patients as they age.

"We also found that patients with monoclonal gammopathy of undetermined significance had shorter survival than comparable people without the condition," says Dr. Rajkumar, which raises the possibility there may be other disorders associated with monoclonal gammopathy of undetermined significance that still need further study."

Research team studied 1,384 patients with two major types of monoclonal gammopathy of undetermined significance: IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance, and associated risk factors health professional use to counsel patients.



Source: Eurekalert